CHARGE syndrome as unusual cause of hypogonadism: endocrine and molecular evaluation.
Coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies (CHARGE) syndrome is a genetic syndrome in which hypogonadism is a frequent feature. A causative mutation within the chromodomain helicase DNA-binding protein-7 gene, which plays an important role in the embryonic development, is present in 2/3 of affected patients. We describe the clinical, hormonal and molecular characteristics of a young man from Ecuador who was diagnosed as having CHARGE syndrome at an adult age. The patient showed several phenotypic features of the syndrome, associated with a prepubertal state and cryptorchidism; hypogonadotrophic hypogonadism with undetectable testosterone levels not responsive to hCG testing and severe osteoporosis were ascertained. Molecular evaluation of the CHD7 gene showed the novel frameshift truncating heterozygous mutation p.Tyr1046Glyfs*23 in exon 12. Magnetic resonance imaging revealed mild hypoplasia of the pituitary gland and hypoplasia of the posterior cranial fossa. Parenteral testosterone therapy led to sexual development over time and, in combination with diphophonate therapy and calcium-vitamin D supplementation, significantly improved bone mineralisation. Early proper hormonal treatment of hypogonadism in patients with complex genetic syndromes is important to achieve normal sexual maturation, improve quality of life and avoid significant comorbidities, such as osteoporosis.
Foppiani
Luca
L
Endocrinology, Galliera Hospital, Genova, Italy. luca.foppiani@galliera.it
Maffè
A
A
Forzano
F
F
D000328:Adult; D058747:CHARGE Syndrome / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000627:therapeutic use; D006063:Chorionic Gonadotropin; D004265:DNA Helicases / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D019587:Dietary Supplements; D004164:Diphosphonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005091:Exons; D016368:Frameshift Mutation; D006801:Humans; D007006:Hypogonadism / Q000209:etiology*; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D010902:Pituitary Gland / Q000503:physiopathology; D011788:Quality of Life; D013739:Testosterone / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D006063:Chorionic Gonadotropin; D004268:DNA-Binding Proteins; D004164:Diphosphonates; D014807:Vitamin D; D013739:Testosterone; D004265:DNA Helicases; C491434:CHD7 protein, human; D002118:Calcium